XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Statement Details (Tables)
9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Short Term Marketable Securities, Available for Sale
Short-Term Marketable Securities
Short-term marketable securities, consisting of equity and debt securities, were as follows:
 
September 30, 2018
 
Cost or Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
 
 
 
 
 
 
 
 
Equity investment in Tandem Diabetes Care, Inc
$
2.0

 
$
40.8

 
$

 
$
42.8

 
 
 
 
 
 
 
 
Debt securities, available for sale
 
 
 
 
 
 
 
U.S. government agencies
$
189.7

 
$

 
$
(0.1
)
 
$
189.6

Commercial paper
67.9

 

 

 
67.9

Corporate debt
1.0

 

 

 
1.0

Total available-for-sale debt securities
$
258.6

 
$

 
$
(0.1
)
 
$
258.5

 
 
 
 
 
 
 
 
Total marketable securities
$
260.6

 
$
40.8

 
$
(0.1
)
 
$
301.3


 
December 31, 2017
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
U.S. government agencies
$
87.5

 
$

 
$
(0.2
)
 
$
87.3

Corporate debt
14.7

 

 

 
14.7

Commercial paper
5.1

 

 

 
5.1

Total marketable securities
$
107.3

 
$

 
$
(0.2
)
 
$
107.1

Net Gain Recognized on Equity Securities
The following table reconciles the net gain recognized on equity securities during the three and nine months ended September 30, 2018 and 2017 to the unrealized gain recognized during the periods on equity securities still held at the reporting date.
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Net gains recognized during the period on equity securities
$
34.9

 
$

 
$
85.0

 
$

Less: Net gains recognized during the period on equity securities sold during the period
(14.1
)
 

 
(44.2
)
 

Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$
20.8

 
$

 
$
40.8

 
$

Inventory
Inventory
 
September 30, 2018
 
December 31, 2017
Raw materials
$
21.8

 
$
20.0

Work-in-process
10.6

 
8.2

Finished goods
22.8

 
17.0

Total
$
55.2

 
$
45.2

Property, Plant and Equipment
Property and Equipment
 
September 30, 2018
 
December 31, 2017
Building (1)
$
6.0

 
$
6.0

Furniture and fixtures
8.5

 
5.7

Computer equipment
28.6

 
25.6

Machinery and equipment
67.6

 
33.8

Leasehold improvements
78.1

 
41.7

Construction in progress
53.1

 
87.6

Total
241.9

 
200.4

Accumulated depreciation and amortization
(72.3
)
 
(54.8
)
Property and equipment, net
$
169.6

 
$
145.6

(1) As described in Footnote 6 “Commitments and Contingencies,” although we do not legally own these premises, we were deemed the owner of the construction project during the construction period of our new manufacturing facility in Mesa, Arizona under a build-to-suit lease arrangement.
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
 
September 30, 2018
 
December 31, 2017
Accounts payable trade
$
57.7

 
$
46.7

Accrued tax, audit, and legal fees
18.3

 
7.1

Accrued rebates
34.7

 
13.9

Accrued warranty
6.4

 
8.8

Accrued other
18.3

 
10.7

Total
$
135.4

 
$
87.2

Accrued Warranty
Accrued Warranty
Warranty costs are reflected in the consolidated statements of operations as product cost of sales. A reconciliation of our accrued warranty costs for the three and nine months ended September 30, 2018 and 2017 were as follows:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Beginning balance
$
7.5

 
$
8.3

 
$
8.8

 
$
9.8

Charges to costs and expenses
3.9

 
5.4

 
11.8

 
13.9

Costs incurred
(5.0
)
 
(5.0
)
 
(14.2
)
 
(15.0
)
Ending balance
$
6.4

 
$
8.7

 
$
6.4

 
$
8.7

Other Liabilities
Other Liabilities
 
September 30, 2018
 
December 31, 2017
Financing lease obligations
$
7.3

 
$
6.7

Deferred rent
7.5

 
8.7

Other
4.6

 
2.8

Total
$
19.4

 
$
18.2